SenesTech Inc  

(Public, NASDAQ:SNES)   Watch this stock  
Find more results for SNES
+0.004 (0.51%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.76 - 0.82
52 week 0.56 - 9.60
Open 0.82
Vol / Avg. 58,270.00/270,524.00
Mkt cap 12.54M
P/E     -
Div/yield     -
EPS -1.34
Shares 15.79M
Beta     -
Inst. own 36%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -17276.47% -3394.65%
Operating margin -17352.94% -3357.55%
EBITD margin - -3245.28%
Return on average assets -170.68% -156.32%
Return on average equity -252.50% -
Employees 27 -
CDP Score - -


3140 N Caden Ct Ste 1
FLAGSTAFF, AZ 86004-9428
United States - Map
+1-928-7794143 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


SenesTech, Inc. is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest's technology and approach targets the reproductive capabilities of both sexes. Using bait stations, ContraPest is dispensed in a palatable liquid formulation that promotes sustained consumption by rodent communities. Its formulation causes both female and male rats to become infertile once they have consumed the dose. The active ingredient in females accelerates the rate at which ovarian follicles (egg structures) are depleted. Once these cells are gone, the animal cannot reproduce. In males, there is a marked reduction in the ability to fertilize eggs and, often complete sterility. ContraPest is designed, formulated and dispensed for handlers and non-target species, such as wildlife and pets in a biodegradable product.

Officers and directors

Loretta Powers Mayer Ph.D. Chairman of the Board, Chief Executive Officer, Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters
Cheryl Ann Dyer Ph.D. President, Chief Research Officer, Director
Age: 64
Bio & Compensation  - Reuters
Grover T. Wickersham Independent Vice Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Thomas C. Chesterman Chief Financial Officer, Executive Vice President, Treasurer, Assistant Secretary
Age: 56
Bio & Compensation  - Reuters
Andrew Altman Chief Operating Officer, Executive Vice President
Bio & Compensation  - Reuters
Kim Patrice Wolin Executive Vice President - Operations, Secretary
Age: 61
Bio & Compensation  - Reuters
Marc Dumont Independent Director
Age: 73
Bio & Compensation  - Reuters
Matthew K. Szot Independent Director
Age: 42
Bio & Compensation  - Reuters
Julia Ann Williams M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters